3-drug regimen shows promise for HCV, study finds

11/14/2012 | MedPage Today (free registration)

A small study from the University of Colorado showed a three-drug therapy for hepatitis C led to undetectable viral levels in 94% of patients with HCV viral genotype 1 without using pegylated interferon and ribavirin. The drugs include a daily dose of daclatasvir and twice daily doses of asunaprevir and BMS-791325.

View Full Article in:

MedPage Today (free registration)

Published in Brief: